Trials / Completed
CompletedNCT06619847
A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 367 (actual)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of VX-993 in treating acute pain after a bunionectomy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-993 | Tablets for oral administration. |
| DRUG | HB/APAP | Capsules for oral administration. |
| DRUG | Placebo (matched to VX-993) | Placebo matched to VX-993 for oral administration. |
| DRUG | Placebo (matched to HB/APAP) | Placebo matched to HB/APAP for oral administration. |
Timeline
- Start date
- 2024-10-29
- Primary completion
- 2025-05-27
- Completion
- 2025-05-27
- First posted
- 2024-10-01
- Last updated
- 2025-06-26
Locations
14 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06619847. Inclusion in this directory is not an endorsement.